[HTML] springer.comFull View

[HTML][HTML] Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction …

L Fattore, D Malpicci, C Milite, S Castellano… - Cell Communication and …, 2020 - Springer
Target therapies based on BRAF and MEK inhibitors (MAPKi) have changed the therapeutic
landscape for metastatic melanoma patients bearing mutations in the BRAF kinase …
被引用次数：7 相关文章 所有 18 个版本
[HTML] nih.gov

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options

J Villanueva, A Vultur, M Herlyn - Cancer research, 2011 - AACR
The mitogen-activated protein kinase (MAPK) pathway has emerged as a central target for
melanoma therapy due to its persistent activation in the majority of tumors. Several BRAF …
被引用次数：199 相关文章 所有 8 个版本
[HTML] nih.gov

[HTML][HTML] Resistant mechanisms to BRAF inhibitors in melanoma

JL Manzano, L Layos, C Bugés… - Annals of …, 2016 - ncbi.nlm.nih.gov
Patients with advanced melanoma have traditionally had very poor prognosis. However,
since 2011 better understanding of the biology and epidemiology of this disease has …
被引用次数：278 相关文章 所有 10 个版本

Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells

I Kozar, G Cesi, C Margue, D Philippidou… - Biochimica et Biophysica …, 2017 - Elsevier
Background Melanoma is an aggressive skin cancer with increasing incidence worldwide.
The development of BRAF kinase inhibitors as targeted treatments for patients with BRAF …
被引用次数：30 相关文章 所有 6 个版本

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma

RW Jenkins, DA Barbie - Cancer Discovery, 2017 - AACR
Identifying molecular and cellular features associated with resistance to targeted
BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches …
被引用次数：6 相关文章 所有 3 个版本
[HTML] nih.gov

[HTML][HTML] mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

G Xue, R Kohler, F Tang, D Hynx, Y Wang, F Orso… - Oncotarget, 2017 - ncbi.nlm.nih.gov
BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi)
were recently approved for therapy of metastatic melanomas harbouring the oncogenic …
被引用次数：23 相关文章 所有 20 个版本
[HTML] nature.com

[HTML][HTML] Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

L Fattore, CF Ruggiero, ME Pisanu, D Liguoro… - Cell Death & …, 2019 - nature.com
Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-
mutated metastatic melanoma. Although this issue has been mitigated by the development …
被引用次数：62 相关文章 所有 10 个版本

Targeting BRAF in melanoma: biological and clinical challenges

M Mandalà, C Voit - Critical reviews in oncology/hematology, 2013 - Elsevier
Melanoma is an aggressive form of skin cancer that causes the greatest number of skin
cancer-related deaths worldwide. In its early stages malignant melanoma can be cured by …
被引用次数：76 相关文章 所有 5 个版本

Crosstalk signaling in targeted melanoma therapy

S Meierjohann - Cancer and Metastasis Reviews, 2017 - Springer
Inhibition of the BRAF/MAPK pathway belongs to the standard therapies for patients with
activating BRAF V600E/K mutations. However, even in well-responding tumors, anti …
被引用次数：21 相关文章 所有 8 个版本

Resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma

H Patel, R Mishra, G Joan - Cancer Research, 2019 - AACR
Melanoma five year survival rates are only 15% for patients with advanced disease. About
50% of melanomas contain the BRAFT1799A transversion which encodes for the …
被引用次数：2 相关文章